SGLT2 Inhibitors and the Risk of Pneumonia and Septic Shock SGLT2 Inhibitors and the Risk of Pneumonia and Septic Shock
SGLT2 inhibitors are commonly used in the treatment of type 2 diabetes. Could these agents also help lower the risk of pneumonia and septic shock in these patients?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2023 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

FDA Approves Brenzavvy (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes
MARLBOROUGH, Mass.--(BUSINESS WIRE) January 23, 2023 --TheracosBio today announced that the U.S. Food and Drug Administration (FDA) has approved Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor. Brenzavvy is... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 23, 2023 Category: Drugs & Pharmacology Source Type: news

FDA Approves New Type 2 Diabetes Drug Bexagliflozin FDA Approves New Type 2 Diabetes Drug Bexagliflozin
Another SGLT2 inhibitor has been approved for type 2 diabetes based on results from 23 clinical trials that included 5000 patients and more than 300 patients who also had stage 3 chronic kidney disease.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 23, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

New SGLT2 Inhibitor Gains FDA Approval for Type 2 Diabetes
(MedPage Today) -- The first oral SGLT2 inhibitor approved by the FDA for treating diabetes in cats is now approved for humans with the disease, drugmaker TheracosBio announced. As an adjunct to diet and exercise, the oral treatment is indicated... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 23, 2023 Category: Cardiology Source Type: news

Diabetes Drug for Cats Now Approved in Humans Too
(MedPage Today) -- The first oral SGLT2 inhibitor approved by the FDA for treating diabetes in cats is now approved for humans with the disease, drugmaker TheracosBio announced. As an adjunct to diet and exercise, the oral treatment is indicated... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 23, 2023 Category: Primary Care Source Type: news

The Year SGLT2 Inhibitors Became Full-Fledged Heart Failure Drugs
(MedPage Today) -- Earlier this year, empagliflozin (Jardiance) won FDA approval for a broader indication in heart failure across the spectrum of ejection fraction. As part of our review of the year's top stories, we follow up on what has happened... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 27, 2022 Category: Urology & Nephrology Source Type: news

Dec 2 2022 This Week in Cardiology Dec 2 2022 This Week in Cardiology
SGLT2 inhibitors, publishing choices, second and third order effects of interventions, decision support, and patient selection for preventive procedures are the topics John Mandrola, MD, discusses in this week ’s podcast.theheart.org on Medscape (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - December 2, 2022 Category: Transplant Surgery Tags: Cardiology Commentary Source Type: news

EMPA-Kidney Seals SGLT2 Inhibitors as'Foundational' for CKD EMPA-Kidney Seals SGLT2 Inhibitors as'Foundational' for CKD
Empagliflozin ' s efficacy in a range of patients with chronic kidney disease in EMPA-Kidney filled evidence gaps and confirmed SGLT2 inhibitors as a key treatment regardless of diabetes status.Medscape Medical News (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - November 22, 2022 Category: Respiratory Medicine Tags: Nephrology News Source Type: news

SGLT2 Inhibitors Safe After Revascularization for Limb Disease SGLT2 Inhibitors Safe After Revascularization for Limb Disease
In patients with type 2 diabetes and peripheral artery disease who undergo revascularization, cardiovascular and renal benefits of the agents were confirmed without increased risk of limb amputation.First Look (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 11, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

Moving the Needle: SGLT2 Inhibitor Role for Kidney Disease Moving the Needle: SGLT2 Inhibitor Role for Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 4, 2022 Category: Internal Medicine Tags: Nephrology News Source Type: news

SGLT2 Inhibitor Role for Isolated Kidney Disease SGLT2 Inhibitor Role for Isolated Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 4, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news

EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 4, 2022 Category: Cardiology Tags: Nephrology News Source Type: news

Empagliflozin and Elderly Patients With HFpEF Empagliflozin and Elderly Patients With HFpEF
Do elderly patients with HFpEF benefit as much as younger patients from treatment with an SGLT2 inhibitor? A new study demonstrates its efficacy across all age groups.Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 17, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Dapagliflozin DELIVERs Regardless of BP in Preserved-EF HF Dapagliflozin DELIVERs Regardless of BP in Preserved-EF HF
The finding may alleviate long-standing concerns that starting modestly diuretic SGLT2 inhibitors in patients with HF might present a hazard to those with a low systolic BP, researchers say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 8, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

Newer Drugs Not Cost-Effective for First-Line Diabetes Therapy Newer Drugs Not Cost-Effective for First-Line Diabetes Therapy
Costs of SGLT2 inhibitors and GLP-1 receptor agonists ' need to be lowered substantially ' to improve health outcomes and prevent health disparities in patients with type 2 diabetes, say researchers.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 4, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news